-
Founded in:
2012-07-20 -
Country:
China -
Address:
Biomedical Park, No. 858 Gaoxin Avenue, Wuhan East Lake New Technology Development Zone (Wuhan Area of Free Trade Zone) -
Tax NO.:
914201005979383918 -
Registered Funds:
230 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Oxaliplatin |
It is a new platinum derivative that acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA rapidly, taking up to 15 minutes, and DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective for some cell lines resistant to cisplatin.
More
It is a new platinum derivative that acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA rapidly, taking up to 15 minutes, and DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective for some cell lines resistant to cisplatin. |
61825-94-3 | 56 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydroxyl camptothecine |
Not described in detail
More
Not described in detail |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydroxyl camptothecine |
Extract from the above information
More
Extract from the above information |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydroxyl camptothecine |
Hydroxycamptothecin (HCPT) is a cell cycle-specific drug that mainly acts in the S phase. Recently, it has been found to have a targeted and selective inhibitory effect on DNA topoisomerase I, which catalyzes the unwinding of supercoiled DNA for replication and transcription. This product inhibits TOPOI and inhibits the replication and transcription of cancer cells. This product has no obvious cross-resistance with other commonly used anticancer drugs.
More
Hydroxycamptothecin (HCPT) is a cell cycle-specific drug that mainly acts in the S phase. Recently, it has been found to have a targeted and selective inhibitory effect on DNA topoisomerase I, which catalyzes the unwinding of supercoiled DNA for replication and transcription. This product inhibits TOPOI and inhibits the replication and transcription of cancer cells. This product has no obvious cross-resistance with other commonly used anticancer drugs. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydroxyl camptothecine |
Hydroxycamptothecin (HCPT) is a cell cycle-specific drug that mainly acts in the S phase. Recently, it has been found to have a targeted and selective inhibitory effect on DNA topoisomerase I, which catalyzes the unwinding of supercoiled DNA for replication and transcription. This product inhibits TOPOI and inhibits the replication and transcription of cancer cells. This product has no obvious cross-resistance with other commonly used anticancer drugs.
More
Hydroxycamptothecin (HCPT) is a cell cycle-specific drug that mainly acts in the S phase. Recently, it has been found to have a targeted and selective inhibitory effect on DNA topoisomerase I, which catalyzes the unwinding of supercoiled DNA for replication and transcription. This product inhibits TOPOI and inhibits the replication and transcription of cancer cells. This product has no obvious cross-resistance with other commonly used anticancer drugs. |
0 |